Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTJME02)

DTT Name	Atrial natriuretic peptide receptor A (NPR1)
Synonyms	NPR1; NPR-A; GC-A; Atrial natriuretic peptide A-type receptor; ANPRA; ANP-A
Gene Name	NPR1
DTT Type	Successful target	[1]
BioChemical Class	Phosphorus-oxygen lyase
UniProt ID	ANPRA_HUMAN
TTD ID	T71230
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
EC Number	EC 4.6.1.2
Sequence	MPGPRRPAGSRLRLLLLLLLPPLLLLLRGSHAGNLTVAVVLPLANTSYPWSWARVGPAVE LALAQVKARPDLLPGWTVRTVLGSSENALGVCSDTAAPLAAVDLKWEHNPAVFLGPGCVY AAAPVGRFTAHWRVPLLTAGAPALGFGVKDEYALTTRAGPSYAKLGDFVAALHRRLGWER QALMLYAYRPGDEEHCFFLVEGLFMRVRDRLNITVDHLEFAEDDLSHYTRLLRTMPRKGR VIYICSSPDAFRTLMLLALEAGLCGEDYVFFHLDIFGQSLQGGQGPAPRRPWERGDGQDV SARQAFQAAKIITYKDPDNPEYLEFLKQLKHLAYEQFNFTMEDGLVNTIPASFHDGLLLY IQAVTETLAHGGTVTDGENITQRMWNRSFQGVTGYLKIDSSGDRETDFSLWDMDPENGAF RVVLNYNGTSQELVAVSGRKLNWPLGYPPPDIPKCGFDNEDPACNQDHLSTLEVLALVGS LSLLGILIVSFFIYRKMQLEKELASELWRVRWEDVEPSSLERHLRSAGSRLTLSGRGSNY GSLLTTEGQFQVFAKTAYYKGNLVAVKRVNRKRIELTRKVLFELKHMRDVQNEHLTRFVG ACTDPPNICILTEYCPRGSLQDILENESITLDWMFRYSLTNDIVKGMLFLHNGAICSHGN LKSSNCVVDGRFVLKITDYGLESFRDLDPEQGHTVYAKKLWTAPELLRMASPPVRGSQAG DVYSFGIILQEIALRSGVFHVEGLDLSPKEIIERVTRGEQPPFRPSLALQSHLEELGLLM QRCWAEDPQERPPFQQIRLTLRKFNRENSSNILDNLLSRMEQYANNLEELVEERTQAYLE EKRKAEALLYQILPHSVAEQLKRGETVQAEAFDSVTIYFSDIVGFTALSAESTPMQVVTL LNDLYTCFDAVIDNFDVYKVETIGDAYMVVSGLPVRNGRLHACEVARMALALLDAVRSFR IRHRPQEQLRLRIGIHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGEALKIHLSSET KAVLEEFGGFELELRGDVEMKGKGKVRTYWLLGERGSSTRG
Function	Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
KEGG Pathway	Purine metabolism (hsa00230 ) Metabolic pathways (hsa01100 ) cGMP-PKG signaling pathway (hsa04022 ) cAMP signaling pathway (hsa04024 ) Vascular smooth muscle contraction (hsa04270 ) Thermogenesis (hsa04714 ) Oxytocin signaling pathway (hsa04921 ) Regulation of lipolysis in adipocytes (hsa04923 ) Renin secretion (hsa04924 ) Aldosterone synthesis and secretion (hsa04925 )
Reactome Pathway	Physiological factors (R-HSA-5578768 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nesiritide	DMFOIA8	Congestive heart failure	BD10	Approved	[1]
------------------------------------------------------------------------------------

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ularitide	DM90AG2	Acute heart failure	BD10-BD13	Phase 3	[2]
Ataciguat	DM35KDA	Neuropathic pain	8E43.0	Phase 2	[3]
Cenderitide	DMCT8EY	Heart disease	BA41-BA42	Phase 2	[4]
PL-3994	DMHUCQS	Asthma	CA23	Phase 2	[5]
------------------------------------------------------------------------------------

References

1	The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004 Feb;19(2):391-9.
2	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015 Mar 21;36(12):715-23.
3	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
4	2011 Pipeline of Nile Therapeutics.
5	In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013 April; 26(2): 229-238.